Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 32 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

P-9688 PD 325901, Free Base, >99%       Prices Reduced (January 2012)

[MEK1/2 Inhibitor III] [PD0325901] [PD-0325901] [PD 0325901]

M.W. 482.19

C16H14F3IN2O4

[391210-10-9]

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 12 mg/mL; soluble in ethanol at 6.3 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• PD 325901 is an inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK).  The potency, solubility and effectiveness of PD 325901 are greatly improved compared to PD 184352 (CI-1040).  Barrett, S.D., et al.  "The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901."  Bioorg. Med. Chem. Lett. 18:  6501-6504 (2008).

• PD 325901 potently inhibited the growth of melanoma cells, with and without BRAF mutation.  It also had an antiangiogenic activity.  Ciuffreda, L., et al.  "Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations."  Neoplasia 11:  720-731 (2009).

• The sensitivity of RAS mutant cancers to MEK inhibitors depends on the activity of the phosphatidylinositol 3-kinase (PI3K) pathway.  Wee, S., et al.  "PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers."  Cancer Res. 69:  4286-4293 (2009).

• The antiproliferative effect on cancer cells of PD 325901 can be determined by a sensitive imaging biomarker, 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography ([18F]FLT-PET).  Leyton, J.,  "Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901."  Mol. Cancer Ther. 7:  3112-3121 (2008).

• PD 325901 potently inhibited the proliferation of thyroid cancer cells with an IC50 of 0.06-0.78 µM.  It also has synergistic inhibitory effects when combined with phosphatidylinositol 3-kinase (PI3K) or NF-κB pathway inhibitors in most thyroid cancer cell lines.  Liu, D. and Xing, M.  "Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways."  Thyroid 18:  853-864 (2008).

• Blockade of MEK/ERK signaling by PD 325901 greatly enhances the cytotoxicity induced by arsenic trioxide (ATO) through a caspase-dependent mechanism in human myeloma cell lines and in tumor cells from patients with multiple myeloma.  Lunghi, P., et al.  "Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways."  Blood 112:  2450-2462 (2008).

• A CAS number previously in use for this compound, 870474-62-7, has been deleted by Chemical Abstracts Service.

• We note that one of our competitors, Reagents Direct, as of March 28, 2011, is claiming 99.7% purity for its PD 325901, Free Base.  This claim is not credible in general chemical terms for this complex organic compound, nor in terms of the sensitivity and reproducibility of generally utilized analytical techniques.

• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, EMD Chemicals - website - Dec 2011, Sigma-Aldrich - website - Jan 2012, Tocris Bioscience - website - Jan 2012, AG Scientific - website - Mar 2012, Wako Chemicals - website - Dec 2011, Santa Cruz Biotech - website - Jan 2012, Cayman Chemical - website - Dec 2011, US Biological - website - Jan 2012, BioVision - website - Mar 2012, Invivogen - website - Feb 2012, Applied Biol. Materials - website - Dec 2011, R&D Systems - website - Jan 2012, Cambridge BioScience - website - Mar 2012, ChemieTek - website - Jan 2012, Axon Medchem - website - Mar 2012, Applied StemCell - website - Jan 2012, Oakwood Products - website - Feb 2012, Stemgent - website - Feb 2012, ShangHai Biochempartner - website - Dec 2011, antibodies-online - website - May 2012, biorbyt.com - website - Mar 2012, Reagents Direct - website - Dec 2011, StemRD - website - Mar 2012, biokits.com - website - Dec 2011, Cellagen Technology - website - Dec 2011, Renova Life - website - Dec 2011, Reliable ChemTech - Google Sites - May 2012, MedKoo BioSciences - website - Feb 2012, SynChem - website - Jan 2012, Medchem Express - website - Apr 2012, AdooQ BioScience - website - Apr 2012, Krackeler Scientific - website - Apr 2012, EMMX BioChemicals - website - May 2012.

*** As of March 28, 2011, Reagents Direct is claiming 99.7% purity for its PD 325901, Free Base.  This claim is not credible in general chemical terms for this complex organic compound, nor in terms of the sensitivity and reproducibility of generally utilized analytical techniques.